Další formáty:
BibTeX
LaTeX
RIS
@article{980400,
author = {Ráčil, Zdeněk and Winterová, Jana and Kouba, Michal and Zak, Pavel and Malaskova, Ludmila and Burešová, Lucie and Tošková, Martina and Lengerová, Martina and Kocmanova, Iva and Weinbergerová, Barbora and Timilsina, Shira and Rolencova, Monika and Cetkovsky, Petr and Mayer, Jiří},
article_location = {Hoboken},
article_number = {6},
doi = {http://dx.doi.org/10.1111/j.1439-0507.2012.02186.x},
keywords = {Voriconazole; plasma concentration; haematological malignancy},
language = {eng},
issn = {0933-7407},
journal = {Mycoses},
title = {Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience},
volume = {55},
year = {2012}
}
TY - JOUR
ID - 980400
AU - Ráčil, Zdeněk - Winterová, Jana - Kouba, Michal - Zak, Pavel - Malaskova, Ludmila - Burešová, Lucie - Tošková, Martina - Lengerová, Martina - Kocmanova, Iva - Weinbergerová, Barbora - Timilsina, Shira - Rolencova, Monika - Cetkovsky, Petr - Mayer, Jiří
PY - 2012
TI - Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience
JF - Mycoses
VL - 55
IS - 6
SP - 483-492
EP - 483-492
PB - WILEY-BLACKWELL
SN - 09337407
KW - Voriconazole
KW - plasma concentration
KW - haematological malignancy
N2 - The objective of this retrospective study was to evaluate results from voriconazole therapeutic drug monitoring (TDM) in haematological patients in routine clinical practice. Between 2005 and 2010, 1228 blood samples were obtained from 264 haematological patients receiving voriconazole for targeted/preemptive treatment of invasive aspergillosis (IA), empirical therapy or prophylaxis. A high-pressure liquid chromatography assay was used to analyse voriconazole concentrations. Clinical and laboratory data were analysed retrospectively. With the exception of omeprazole administration, there was no relevant relationship between measured voriconazole concentrations and drug dose, route administration, age, gender, CYP2C19*2 genotype, gastrointestinal tract abnormality, administration via nasogastric tube, serum creatinine, and liver enzymes. However, per patient analysis identified significant role of individual voriconazole dose and drug form change on measured plasma concentration. Measured voriconazole concentrations did not correlate with the treatment outcome of patients with IA. We only identified a limited number of adverse events related to voriconazole therapy; however, the median plasma concentration was not different from concentrations measured in samples without reported toxicity. Our retrospective study has suggested that routine monitoring of voriconazole plasma concentrations has probably only a limited role in daily haematological practice.
ER -
RÁČIL, Zdeněk, Jana WINTEROVÁ, Michal KOUBA, Pavel ZAK, Ludmila MALASKOVA, Lucie BUREŠOVÁ, Martina TOŠKOVÁ, Martina LENGEROVÁ, Iva KOCMANOVA, Barbora WEINBERGEROVÁ, Shira TIMILSINA, Monika ROLENCOVA, Petr CETKOVSKY a Jiří MAYER. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. \textit{Mycoses}. Hoboken: WILEY-BLACKWELL, 2012, roč.~55, č.~6, s.~483-492. ISSN~0933-7407. doi:10.1111/j.1439-0507.2012.02186.x.
|
